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ABSTRACT
Replication Protein A (RPA) is a single-stranded
DNA-binding protein essential for DNA replication,
repair, recombination and cell-cycle regulation.
A human homolog of the RPA2 subunit, called
RPA4, was previously identified and shown to be
expressed in colon mucosal and placental cells;
however, the function of RPA4 was not determined.
To examine the function of RPA4 in human cells, we
carried out knockdown and replacement studies to
determine whether RPA4 can substitute for RPA2 in
the cell. Unlike RPA2, exogenous RPA4 expression
did not support chromosomal DNA replication and
lead to cell-cycle arrest in G2/M. In addition, RPA4
localized to sites of DNA repair and reduced c-H2AX
caused by RPA2 depletion. These studies suggest
that RPA4 cannot support cell proliferation but can
support processes that maintain the genomic integ-
rity of the cell.
INTRODUCTION
In order to proliferate and maintain genomic integrity, a
cell must recognize and repair DNA damage and replicate
DNA with high ﬁdelity. One protein intricately involved
with these processes is the single-stranded DNA (ssDNA)-
binding protein, Replication Protein A (RPA) (1–3). RPA
was originally isolated as a factor essential for simian virus
40 (SV40) DNA replication (1) and has since been shown
to have integral roles in DNA repair, recombination,
chromosome stability and cell-cycle regulation (1–3).
In addition to ssDNA binding, RPA interacts with a
number of proteins involved in genome maintenance and
cell-cycle control (e.g. XPA, ATR-ATRIP, p53) (4), and
mutations in RPA or in proteins that interact with RPA
are often correlated with human disease, particularly
cancer. It has been shown that a cancer predisposing
mutation in BRCA2 (Y42C) disrupts the interaction
between BRCA2 and RPA (5). Furthermore, a single
amino acid substitution (L221P) in RPA1 results in a
high rate of lymphoid tumor development and shortened
lifespan when heterozygous in mice (6). This mutation is
analogous to a mutation, rfa1-t48, originally isolated in
the budding yeast Saccharomyces cerevisiae that displays
multiple DNA damage sensitivities (7). It has also been
demonstrated that increased expression of RPA1 and
RPA2 correlates with increased severity of colon cancer
(8). This is not surprising, since RPA is essential for cells
to proliferate (1).
Although ‘canonical’ RPA is composed of the subunits
RPA1, RPA2 and RPA3, some organisms, such as seed
plants (e.g. rice, Arabidopsis thaliana) and some protists,
contain multiple RPA subunit genes that form multiple
RPA complexes (9,10). In the case of plants, the diﬀerent
RPA complexes appear to have diﬀerent functions (11).
In human cells, a single homolog of the RPA2 subunit has
been identiﬁed, called RPA4. RPA4 was isolated through
a HeLa cell library interaction-trap/yeast two-hybrid
screen as a factor that interacts with RPA1 (12). Initial
studies showed that RPA4 also interacts with RPA3, but
not with RPA2, and immunoprecipitation of RPA1
coprecipitates RPA4 after expression in rabbit reticulocyte
lysate or in 293 cells (12). RPA4 transcribed/translated
in vitro with RPA1 and RPA3 is retained on ssDNA cel-
lulose, suggesting that this ‘alternative’ complex has
ssDNA-binding capability (12). More recently, it has
been shown that RPA4 forms a stable complex with
RPA1 and RPA3 and has solution properties indistin-
guishable from canonical RPA (13).
The studies presented here focus on understanding the
function of RPA4 in human cells. We present a genomic
analysis of the RPA4 gene that indicates that RPA4 is
mammalian-speciﬁc. We show that expression of RPA4
*To whom correspondence should be addressed. Tel: +1 319 335 6784; Fax: +1 319 384 4770; Email: marc-wold@uiowa.edu
Present address:
Stuart J. Haring, North Dakota State University, Department of Chemistry and Molecular Biology, Fargo, ND 58108-6050, USA.
846–858 Nucleic Acids Research, 2010, Vol. 38, No. 3 Published online 26 November 2009
doi:10.1093/nar/gkp1062
 The Author(s) 2009. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.5), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.in cells does not support chromosomal DNA replication
or cell-cycle progression. However, we present evidence
that RPA4 functions in cellular DNA metabolism.
RPA4 can localize to DNA repair foci and appears
to participate in the cellular DNA damage response.
We identify the region of RPA4 responsible for the
observed phenotypes. These ﬁndings suggest that RPA4
expression may be involved in maintaining cell quiescence.
MATERIALS AND METHODS
Exogenous RPA expression constructs
To identify exogenous expression of RPA in HeLa cells,
enhanced green ﬂuorescent protein (EGFP)-tagged RPA1,
RPA2, RPA3 and RPA4 constructs were generated;
EGFP-tagged RPA1 (pEGFP-hsRPA70), RPA2
(pEGFP-hsRPA32) and RPA3 (pEGFP-hsRPA14) were
generated previously (14). EGFP-RPA4 (pEGFP-
hsRPA4) was generated by PCR ampliﬁcation of the
RPA4 coding region from pBABE-puro-RPA4 (12)
using primers O-606 (50-CAGATCTCGAGGTGGAGG
CATGAGTAAGAGTGGGTTTGGG-30) and O-607
(50-CCCGCGGTACCTCAATCAGCAGACTTAAAAT
G-30) and inserted into the XhoI-KpnI sites of pEGFP-C1
(Clontech). EGFP-scRPA32 (pEGFP-scRPA32) was
generated by PCR ampliﬁcation of the RFA2 coding




TGTCATCAAAAG-30) and inserted into the BglII-KpnI
sites of pEGFP-C1 (Clontech). All constructs were con-
ﬁrmed by sequencing.
RPA2/RPA4 ‘hybrid’ constructs were generated by ﬁrst
creating a ‘cassettized’ EGFP-RPA2 construct (pEGFP-
hsRPA32-AS). The QuikChange XL Site-Directed
Mutagenesis Kit was used to generate a unique SpeI site
between the DNA-binding domain (DBD) and the
C-terminal region containing the winged-helix domain
(WHD) on plasmid pEGFP-hsRPA32 with primers
O-635 (50-GGTACTAAGCAAAGCCACTAGTCAGCC
CTCAGCAGGGAG-30) and O-636 (50-CTCCCTGC
TGAGGGCTGACTAGTGGCTTTGCTTAGTACC-30).
This plasmid (pEGFP-hsRPA32-S) was then used to
generate a unique AﬂII site between the phosphorylation
domain (PD) and the DBD with primers O-644 (50-GCCG
AAAAGAAATCAAGACTTAAGGCCCAGCACATT
GTG-30) and O-645 (50-CACAATGTGCTGGGCCTTA
AGTCTTGATTTCTTTTCGGC-30). PCR was used to
amplify the putative PD, the putative DBD, or the
C-terminus of RPA4, and these fragments were used to
replace the corresponding domain of RPA2. Primers used
to amplify the RPA4 PD were O-606 and O-678 (50-TGG
GCCTTAAGCTTAGGTCTTTGGGTCTTAATAGCA
G-30), to amplify the RPA4 DBD were O-676 (50-CAAGA
CTTAAGGCCCAGGACGTTGTACCGTGTAACGTG
AACC-30) and O-677 (50-GGCTGACTAGTGGCTTTAT
CCAGCATCATGTGTGC-30), and to amplify the RPA4
C-terminus were O-679 (50-AAGCCACTAGTCGTCGT
GATACCACTGTAGAAAGTG-30) and O-607.
RPA2 or RPA4 ‘core’ plasmids, containing only the
DBD of either gene, were constructed using standard
PCR and cloning techniques. Brieﬂy, DBD-D was
ampliﬁed with primers O-672 (50-CAGATCTCGAGGT
GGAGGCCAGCACATTGTGCCCTGTACTATATC
TC-30) and O-673 (50-CCCGCGGTACCTCAGGCTTTG
CTTAGTACCATGTGTGC-30) and cloned into the
XhoI-KpnI sites of pEGFP-C1. DBD-G was ampliﬁed
with primers O-674 (50-GCGGCAGATCTGGTGGAG
GCCAGGACGTTGTACCGTGTAACGTGAACC-30)
and O-675 (50-CCCGCGGTACCTCAGGCTTTATCCA
GCATCATGTGTGC-30) and cloned into the BglII-KpnI
sites of pEGFP-C1.
Tissue culture, RNA interference (RNAi) and exogenous
RPA expression
HeLa cells were grown in Dubellco’s Modiﬁed Eagle’s
Medium (DMEM) supplemented with 10% bovine calf
serum (BCS) at 37 C and 5% CO2. Small interfering
RNA (siRNA) targeting the 30 untranslated region
(UTR) of RPA2 mRNA was generated (Dharmacon).
The sequence of the siRNA for RPA2 was identical to
previously published siRNA (16). Silencer negative
control #2 RNA (Ambion) was used as a control to
examine the speciﬁcity of RPA2 knockdown.
HeLa cells were seeded in six-well tissue culture plates at
2 10
5 cells/well for 18–24h. Cells were then transfected
with 200 pmol RPA2 siRNA using Lipofectamine 2000
(Invitrogen) at time zero (t=0). At 24h post-transfection
of siRNA (t=24), the media was removed from the cells
and fresh DMEM/10% BCS was added to each well. The
cells were then transfected with 250ng of the appropriate
plasmid DNA using Lipofectamine 2000. At 48h
post-transfection of siRNA (t=48), the media was
removed and fresh DMEM/10% BCS was added to the
cells. The cells were then grown until collected for protein,
immunoﬂuorescence (IF), or ﬂow cytometry.
Cell lysates and protein detection
Cells were trypsinized and collected at various times
post-transfection and pelleted at 1.5 rcf for 5min. The
cells were washed once with phosphate buﬀered saline
(137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4 7H2O,
1.4mM KH2PO4) and pelleted at 1.5 rcf for 5min. Cells
were then lysed in RIPA buﬀer [1% (w/w) NP-40, 1%
(w/v) sodium deoxycholate, 0.1% (w/v) SDS, 150mM
NaCl, 10mM sodium phosphate (pH 7.2), 2mM EDTA,
50mM sodium ﬂuoride, 0.2mM sodium vanadate, 1 mg/
ml aprotinin] and placed at  80 C. Cell lysates were
thawed, sonicated with a microtip at setting four using a
Sonic Dismembrator 550 (Fisher) by pulsing for 3s four
times, and the protein was quantitated using the DC assay
(Bio-Rad). Equal amounts (100 mg) of protein were loaded
on an 8–14% gradient SDS–PAGE gel and run at 40W
for 1.5–2h. Gels were electroblotted onto Bio-Rad
nitrocellulose membrane at 0.2 mA for 16–20h at 4 C.
The membrane was blocked with 10% non-fat dry milk/
1 TBS/0.1% Tween 20 for 30min. The blocking solution
was removed and primary antibody in 10% non-fat dry
milk/1 TBS/0.1% Tween 20 was added to the membrane
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Primary antibodies used were N2.2 (rabbit polyclonal to
RPA1 and RPA2) or JL-8 (monoclonal to GFP;
Clontech) at 1:500 and 1:6000, respectively. The
membrane was then washed three times with 1 TBS/
0.1% Tween 20. The secondary antibody goat anti-mouse
IgG horseradish peroxidase (HRP) (Sigma) or goat
anti-rabbit IgG HRP (Sigma) was diluted 1:20000 in
1 TBS/0.1% Tween 20, added to the membrane, and
incubated for 1–2h at room temperature. The membrane
was washed four times with 1 TBS/0.1% Tween 20.
SuperSingal West Pico Chemiluminescent Substrate
(Pierce) was used to detect HRP.
Induction of DNA damage and ﬂuorescence microscopy
To examine the localization of RPA to DNA, HeLa cells
were treated as described for RNAi above and grown for
90–96h post-transfection of RPA2 siRNA. Cells either
had no additional treatments (un-stressed) or were
incubated for the ﬁnal 4h with indicated amount
camptothecin or etoposide (DNA damaged). The cells
were then ﬁxed, extracted to leave only chromatin
bound protein, and prepared for ﬂuorescence microscopy
as described (17).
Flow cytometry and cell synchronization
Cells were treated, assayed, and designations for ﬂow
cytometry are as described (17). Where indicated, DNA
damage was induced as described above. Synchronized
cells were generated with a 27h treatment with 5mg/ml
aphidicolin (Sigma) starting at 57h (t=57)
post-transfection of RPA2 siRNA. At 84h (t=84)
post-transfection, cells were released from aphidicolin
block by rinsing the cells once with 2ml PBS and adding
2ml fresh medium. Cells were collected at indicated time
after release and examined by ﬂow cytometry.
Molecular modeling of RPA4 and derivatives
Geno3D (http://geno3d-pbil.ibcp.fr) was used to obtain
predicted protein structures for the DBDs of RPA4 (aa
44–171), RPA2-basic (aa 44–171) and RPA4-acidic (aa
44–172) or the C-terminus of RPA4 (aa 196–263).
Brieﬂy, RPA4, RPA2-basic and RPA4-acidic were
modeled against known structures of RPA2 DBD-D
[2PQA-chain C (18), 2PI2-chain A (18), 1L10-chain B
(19) and 1QUQ-chain A (20)]. All structures (known and
predicted) were examined using Swiss-PDB Viewer and
displayed using Mac MegaPOV.
Statistical analysis
To determine the statistical signiﬁcance of diﬀerences in
the percentage of cells in S- or G2/M-phase, cell-cycle
analysis software integrated into FlowJo (TreeStar) was
ﬁrst used to measure these values for cells expressing
each construct. These values were then entered into
InStat (GraphPad) as raw data, and the mean, standard
deviation, sample size, standard error of the mean, and
upper and lower conﬁdence limits were determined.
A one-way analysis of variance (ANOVA) was performed
using the Tukey–Kramer multiple comparisons test.
InStat also tested the data for normality using the
Kolmogorov–Smirnov test. Where statistical signiﬁcance
is mentioned, the type of test, q-value and corresponding
P-value are shown. For S- or G2/M-phase statistics,
a q-value >4.732 is considered signiﬁcant (P<0.05).
RESULTS
Genomic analysis of RPA4 sequences
RPA4 was identiﬁed prior to the sequencing of the human
genome. With sequencing and annotation of the human
and other genomes, it was possible to analyze the RPA4
gene and examine its evolutionary conservation. This
analysis identiﬁed three interesting features of the RPA4
gene. First, RPA4 is intronless, suggesting that RPA4
arose from a viral- or retrotransposon-mediated gene
duplication event. Second, RPA4 resides on the
X-chromosome at position q21.33. Third, RPA4 lies in
the intron of a known coding gene, diaphanous 2
(DIAPH2). DIAPH2 encodes a formin-related actin-
binding protein (21,22). Expression of RPA4 is not well
characterized, but available public data indicates that
RPA4 is expressed in diﬀerent tissues than DIAPH2
(http://genome.ucsc.edu/), indicating that it is
independently regulated.
The RPA4-related sequences are only found in
mammals. Primates (human, chimpanzee, orangutan,
monkey and marmoset) and horse contain complete
coding sequences for RPA4 region (Figure 1). Marmoset
RPA4 is the only gene not located on the X-chromosome.
Other mammals examined (e.g. cow, elephant, dog, cat,
rabbit, mouse, rat and armadillo) have partial RPA4-
related sequences or a RPA4 pseudogene at the equivalent
position of the X-chromosome. We are unable to identify
RPA4-related sequences in any non-mammalian genome,
and conclude that functional RPA4 genes are found only
in primates and a few other mammals.
Rescue of RPA2 depleted cells by exogenous
RPA subunit expression
To determine the function of RPA4 in cells, we used a
knockdown-replacement strategy. A short interfering
RNA (siRNA) was used to target the 30 untranslated
region of RPA2 mRNA for degradation in HeLa cells.
A decrease in RPA2 protein was observed at 48h
post-transfection of siRNA; only  30% of RPA2
remained in the cells (Figure 2a). No change in RPA2
levels was observed in mock treated cells and in cells
transfected with a non-speciﬁc control siRNA (Figure 2a
and data not shown). Maximal knockdown of RPA2
occurred between 72 and 96h post-transfection and
resulted in coordinate depletion of RPA1 protein
[Figure 2a; as previously observed in ref. (23)].
Although RPA2 protein levels decreased by 70% at 48h
post-transfection, a deﬁnitive cell-cycle phenotype was not
observed until 72–96h (Figure 2b). RPA2 depletion
resulted in a decrease in G1-phase cells and an increase
in cells accumulating in early S-phase (Figure 2b),
characterized by an unequal (asymmetric) distribution of
848 Nucleic Acids Research, 2010,Vol. 38,No. 3Figure 1. Alignment of known and putative RPA4 and RPA2 from six mammalian species. RPA4 and RPA2 protein sequences are from Homo
sapiens (Hosa) (NP037479, NP002937) and the predicted sequences from Pan troglodytes (Patr) (XP001136507, XP513251), Pongo abelii (Poab)
(CAH90667), Callithrix jacchus (Caja) (RPA4 protein derived from DNA Contig10151:1273-53091; RPA2 protein derived from DNA
Contig150:1594-1135700), Macaca mullata (Mamu) (XP001088106) and Equus caballus (Eqca) (XP001491922, XP001500549). Amino acid positions
are denoted at the beginning and end of each line of sequence. Alignment was performed and identical (*), conserved (:), and semiconserved (.)
residues are denoted below each alignment by TCOFFEE. Grey and black shaded residues denote regions of least conservation or major charge
diﬀerence between RPA2 and RPA4 noted in Keshav et al. (12). Black shaded residues also denote amino acids swapped between RPA2 and RPA4
in our studies. The N-termini containing the putative phosphorylation domain are denoted with lowercase letters, the OB-fold DBDs are identiﬁed by
UPPERCASE letters, and the C-termini are denoted with lowercase italics.
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results in a replication defect. Another striking phenotype
was an increase in cells with sub-G1 DNA content and
reduced forward and side light-scattering properties after
96h (Supplementary Figure S1a). These features are indic-
ative of cell death in RPA2-depleted cells and consistent
with the observation of the formation of fragmented and
micronuclei at these times (Figure 2c). This suggests that
depleted cells are undergoing apoptosis, and that RPA2 is
essential for proliferating human cells.
We generated N-terminally tagged GFP-RPA2 and
GFP-RPA4 constructs and transfected them into
RPA2-depleted cells to examine RPA4 function in the
cell. GFP-expressing cells were identiﬁed using ﬂow
cytometry (Figure 3a, left column; GFP-RPA2) and
showed a cell-cycle distribution similar to mock-transfected
cells (Figure 3a, right column). This conﬁrmed that exoge-
nous GFP-tagged RPA2 was expressed and was functional
in the cell. We also expressed GFP-tagged RPA1 or RPA3
in RPA2-depleted cells and found that GFP-RPA1 expres-
sion was undetectable, while GFP-RPA3 was expressed at a
slightly lower level (Supplementary Figure S1b). This
suggests that RPA2 is necessary to stabilize RPA complex
formation. These ﬁndings are consistent with previous
studies showing that RPA2 and RPA3 are stable in the
cell when RPA1 is depleted (14) and form a subcomplex
in solution in the absence of RPA1 (24).
In contrast to RPA1, GFP-RPA4 was abundantly
expressed in the absence of RPA2 (Figure 3a, left
column, see also Figure 5b). RPA4-positive cells had a
more symmetric distribution of S-phase cells (Figure 3a)
than RPA2-depleted cells (asymmetric S-phase distribu-
tion); however, there was a detectable increase in
S-phase cells compared to cells rescued with exogenous
RPA2 (Figure 3b). The percentage of RPA4-expressing
cells in S-phase was statistically higher than
mock-transfected (RPA2-expressing) cells (Tukey–
Kramer; q=6.823; P<0.001) and not statistically diﬀer-
ent from RPA2-depleted cells (Tukey–Kramer; q=1.909;
P>0.05). In addition, RPA4-positive cells had a cell-cycle
defect; they accumulated in G2/M (Figure 3a and b). This
G2/M arrest was statistically signiﬁcant compared
to mock-transfected cells (Tukey–Kramer; q=6.048;
P<0.01), and was alleviated upon addition of caﬀeine
(not shown), a potent checkpoint inhibitor (25). DNA
damaging agents caused cells expressing exogenous
RPA2 or RPA4 to cell-cycle arrest (Figure 3c).
Cell-cycle arrest was observed in either S- or G2/
M-phase depending on the concentration of DNA
damaging agent and length of exposure (Figure 3c and
data not shown). The damage-dependent arrest was
alleviated upon the addition of caﬀeine (not shown),
demonstrating that it was the result of checkpoint activa-
tion. Cells depleted for RPA2 and treated with DNA
Figure 2. Knockdown of endogenous RPA2. (a) Examination of mock and RPA2 siRNA knockdown by western blot showing RPA2 and RPA1
depletion. Number of hours post-transfection of siRNA are denoted above each lane. R, 200ng puriﬁed recombinant human RPA. (b) Cell-cycle
analysis of mock or RPA2 siRNA knockdown. DNA content was analyzed by ﬂow cytometry and plotted as number of cells versus DNA content
(FL2-A ﬂuorescence). Cells with unreplicated DNA content are labeled as G1 phase, cells with replicated DNA content are labeled G2/M phase and
cells with intermediate DNA content are labeled S-phase. The number of hours post-transfection of mock or RPA2 siRNA is designated in the upper
right corner of each histogram. (c) Microscopic examination of nuclei following mock or RPA2 depletion. Hours post-transfection are designated at
the upper left of each image. Arrows designate fragmented and micronuclei formation.
850 Nucleic Acids Research, 2010, Vol. 38,No. 3damage showed the same early S-phase arrest observed in
un-damaged cells. We conclude that the early S-phase
arrest is a terminal phenotype of RPA2 depletion.
RPA4 function in DNA repair and apoptosis
It has been shown that RPA2 localizes to sites of repair
after DNA damage (16). This localization is observed in
cells that have been exposed to DNA damage and
extracted to visualize tightly associated, chromatin
bound protein. To determine whether RPA4 has simi-
lar localization, cells expressing endogenous RPA2 or
RPA2-depleted cells expressing GFP-RPA2 or GFP-
RPA4 were treated with camptothecin. Figure 3d shows
that like both endogenous and exogenous RPA2, RPA4
localized to foci after DNA damage. To conﬁrm that the
Figure 3. Rescue of RPA2 knockdown by exogenous RPA2 or RPA4 expression. (a) Cells were either mock- or RPA2 siRNA-transfected
(designated above the dot-plots and histograms). After 24h, the cells were transfected with either empty vector (EV) or with an RPA
subunit-containing vector (designated in the upper right corner of each dot-plot and histogram). At 90h post-transfection, cells were stained for
ﬂow cytometry, and exogenous RPA2- or RPA4-positive cells were identiﬁed based on their GFP expression (FL1-H ﬂuorescence). The DNA
content of GFP-positive (RPA2- or RPA4-expressing) cells (right box of each dot-plot) was plotted as a histogram. The DNA content of
GFP-negative cells (left box of each dot-plot) was plotted for all samples transfected with EV. (b) Quantitation of the percentage of cells in G1,
S and G2/M phases (denoted below bar graph) of the cell cycle. Error bars represent standard deviation. (c) Response to DNA damage. After 24h
transfection (where indicated) with siRNA, cells were either mock-transfected or transfected with indicated RPA subunit-containing vec-
tor (designated in upper right). Cells were treated as described in (a). Top row: no additional treatments, bottom row: cells incubated for
ﬁnal 24h with 0.2 mM camptothecin (Cpt). DNA content of GPF-negative (mock) or GFP-positive cells (RPA2, RPA4) shown with percent of
cells in S-phase indicated. (d) Localization of RPA2 or RPA4 to repair foci. Cells were treated as in (a) and DNA damage was induced by treatment
with 2 mM camptothecin for 4hr. Lower panels show RPA2 or RPA4 localization. For mock-transfected cells, RPA2 antibody (71-9A) was used to
detect endogenous RPA2. For RPA2-depleted cells, GFP was detected for RPA2 or RPA4. Upper panels show corresponding nuclei stained with
DAPI.
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co-localization with the phosphorylated forms of two
proteins known to localize to sites of DNA in the DNA
damage response: phosphorylated H2AX (g-H2AX) and
phosphorylated Chk2 (P-Chk2) (26,27). After DNA
damage, both RPA2 and RPA4 co-localize to foci with
g-H2AX (Figure 4a) and with P-Chk2 (Figure 4c). The
RPA2 homolog from yeast (S. cerevisae) was used as a
control for these experiments. Yeast RPA2 (sc2) does
not form a complex with human RPA subunits and was
not observed to form foci (Figure 4). This demonstrates
that localization is dependent on a human RPA2 isoform
and is not an artifact of the expression system. In the
absence of DNA damage, foci were not observed in cells
expressing RPA2 or sc2. However, RPA4 and g-H2AX
foci but not P-Chk2 foci were observed in cells expressing
RPA4 in the absence of DNA damage. This suggests
RPA2-depleted cells expressing RPA4 contain abnormal
DNA structures, but that these structures do not cause
Chk2 activation.
The G2/M arrest and foci formation observed in
RPA4-expressing cells in the absence of DNA damage
could be caused by a deﬁciency in either replication or
DNA repair leading to checkpoint activation (or both).
To try to determine the checkpoint status in these cells,
total g-H2AX and P-Chk2 staining was examined by ﬂow
cytometry. Unstressed RPA2 expressing cells have low
levels of g-H2AX staining (left peak, Figure 4b).
Unstressed cells expressing yeast RPA2 also mostly have
low levels g-H2AX staining cells; however, a small popu-
lation of cells was observed that stain very strongly for
g-H2AX (Figure 4b). Since the cells examined by ﬂow
cytometry have not been extracted, these two populations
cannot be directly compared to extracted cells observed by
Figure 4. Co-localization of RPA forms with g-H2AX or phosphorylated Chk2. For all panels, cells were treated with RPA2 siRNA and transfected
with indicated GFP-RPA fusion expression plasmid [RPA2, RPA4, or yeast RPA2 (sc2)] as described in Figure 3. Cells were then either grown
untreated or in the presence of 20mM camptothecin (a and b)o r3 4mM etoposide (c and d) for last 4h. Cells were prepared for immuno-ﬂuorescence
as described in ‘Materials and Methods’ section and stained with (a) rabbit anti-g-H2AX (phospho-Ser139) or (b) anti-phospho-Chk2 (Thr68;
P-CHK2) antibodies (Cell Signaling Technology). Arrows indicated representative foci. Antibodies were used according to the manufacturer’s
recommendations and detected using Texas Red-X goat anti-rabbit IgG (Invitrogen). Chromatin-associated RPA was visualized using intrinsic
green ﬂuorescence and nuclei (DNA) were visualized with DAPI staining. Flow cytometry samples examining total g-H2AX (b) and
phospho-Chk2 checkpoint activation (d) were prepared as described in ‘Materials and Methods’ section. RPA2-depleted cells expressing
non-functional yeast RPA2 (green histogram), RPA2 (blue histogram), or RPA4 (red histogram) were stained with (b) anti-g-H2AX Alexa Fluor
647 (Cell Signaling Technology) or (d) anti-phospho-Chk2 (as above) and R-phycoerythrin goat anti-rabbit IgG (Invitrogen). Fluorescence intensity
shown on a log scale.
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(Figure 2c, Supplementary Figure S1a) or RPA1 depletion
(14,23) appear to cause apoptosis, we propose that the
high g-H2AX staining cells indicate apoptotic DNA frag-
mentation with robust g-H2AX staining (28). When
RPA4 was expressed in unstressed cells, no high staining
g-H2AX cells were observed. This argues that expression
of RPA4 prevents the formation of this population of
cells. Most of the unstressed cells expressing RPA4 had
low g-H2AX staining but some cells were observed with
slightly elevated g-H2AX staining (Figure 4b). The later
population is consistent with some g-H2AX foci being
observed in unstressed cells expressing RPA4.
After DNA damage, a population with high g-H2AX
staining was observed with all forms of exogenous protein
consistent with a normal cellular DNA damage response
(Figure 4b). With all three forms of exogenous RPA, we
observed low levels of P-Chk2 in the absence of DNA
damage and uniform, high levels of P-Chk2 after DNA
damage (Figure 4d). Taken together with the g-H2AX
data, these results indicate that cells expressing RPA4
can support checkpoint activation and that expression of
RPA4 can suppress cell death caused by RPA2 depletion.
Further they indicate that RPA4-expressing cells contain
some type of abnormal DNA structure that is suﬃcient to
cause elevated g-H2AX but not Chk2 activation (low
P-Chk2). It is most likely that the abnormal DNA struc-
ture is triggering G2/M checkpoint activation observed in
RPA4-expressing cells.
RPA4 function DNA replication
The RPA4-expressing cells had a similar percentage of
cells in S-phase as RPA2 depleted cells (Figure 3b). This
suggests that RPA4 may have a defect in DNA replica-
tion. To conﬁrm these ﬁndings, we examined the ability of
RPA4 to support DNA replication in synchronized cells.
Cells were treated with the DNA polymerase inhibitor
aphidicolin (APH) (29) to synchronize cells at the G1/S
boundary. The cells were subsequently released into
APH-free medium, and progression through S-phase was
monitored. As expected, RPA2- and RPA2-depleted cells
expressing a control, yeast RPA2 (Sc2), were unable to
progress through S-phase (Figure 5a). Exogenous
RPA2-expressing cells were proﬁcient for DNA replica-
tion as indicated by a population of cells progressing
through S-phase by 8h after APH release (Figure 5a). In
contrast, the RPA4-expressing cells were unable to
progress through S-phase (Figure 5a). These results are
consistent with the ﬁnding that an RPA complex contain-
ing RPA4 in place of RPA2 is unable to support SV40
DNA replication in vitro (13). We conclude that RPA4 is
unable to support chromosomal DNA replication. We
hypothesize that the g-H2AX/RPA foci and the G2/M
arrest observed in proliferating cells containing RPA4 is
caused by incomplete chromosomal DNA replication.
Identifying the region responsible for RPA4 phenotypes
RPA2 can be divided into three regions (Figure 5b): (i) the
N-terminal phosphorylation domain (PD, aa 1–44), (ii)
the central DBD-D (aa 45–172) and (iii) the C-terminal
region (aa 173–270) containing a linker and a WHD.
Amino acid sequence analysis revealed that RPA4 shares
47% amino acid sequence identity and 63% amino
acid similarity to RPA2 and appears to have a similar
domain organization. The similarity of the putative
phosphorylation domain, putative DBD (DBD-G), and
the putative WHD (without the linker) of RPA4 are 67,
71, 52%, respectively. To identify the region(s) of RPA4
responsible for the diﬀerences in activity, we generated a
‘cassettized’ GFP-RPA2 by inserting a unique restriction
site immediately upstream and downstream of each region
(Figure 5b). Each region of RPA2 was then substituted
with the corresponding region of RPA4 producing three
hybrid forms, called 422, 242 and 224, where numerals
indicate the source of each of the three domains
(Figure 5b).
The GFP-RPA2/RPA4 ‘hybrid’ constructs were
expressed (Figure 5c) and examined in cells as described
above. All hybrid constructs reduced the percentage of
cells in S-phase compared to RPA2-depleted or RPA2-
depleted/RPA4-expressing cells (Figure 5d). However,
only the 242 hybrid construct containing DBD-G dis-
played the G2/M arrest phenotype (Figure 5d and e).
We conclude that DBD-G is not able to substitute for
DBD-D in RPA2 (i.e. DBD-D is essential for chromo-
somal DNA replication).
These studies using asynchronous cell cultures indicated
that the hybrid constructs can rescue, to varying degrees,
the replication defect due to RPA2 depletion, whereas
RPA4 expression cannot. We next tested each hybrid in
cells synchronized with aphidicolin. The hybrid constructs
supported S-phase progression to diﬀerent extents:
422-expressing cells entered S-phase as eﬃciently as
RPA2-expressing cells, 224-expressing cells entered
S-phase (but less eﬃciently) and very few 242-expressing
cells were able enter S-phase (Figure 5a). We conclude that
the putative phosphorylation domain of RPA4 has no
eﬀect on replication, the C-terminus of RPA4 aﬀects the
eﬃciency of replication, and that the DBD of RPA2 is
essential for cellular replication, since only hybrid 242,
which contains the putative DBD of RPA4, completely
prevented replication. These results are consistent with
the previous ﬁnding that the DBD of RPA2 is the only
essential domain required for cell viability in unstressed
yeast cells (30,31). The replication defect cannot
be directly attributed to diﬀerences in DNA-binding
aﬃnities, because Mason et al. (13) demonstrated that
the alternative RPA complex (containing RPA4) binds
ssDNA similarly to wild-type RPA (containing RPA2).
Only hybrid 242 caused G2/M arrest similar to RPA4
(Figure 5d and e). To explore a possible cause for this
G2/M arrest, we examined the ability of the hybrid con-
structs to participate in genome maintenance by
examining g-H2AX staining. All hybrid constructs had
g-H2AX staining similar to RPA4: no high g-H2AX
staining cells were observed. In addition, all hybrids
were localized to foci after DNA damage
(Supplementary Figure S2). This suggests that all of the
domains of RPA4 can substitute for the comparable
domain of RPA2 in these cellular processes.
Nucleic AcidsResearch, 2010, Vol.38,No. 3 853Figure 5. ‘Cassettized’ RPA2 and complementation of RPA2 knockdown by exogenous RPA2/RPA4 ‘hybrid’ and ‘core’ constructs. (a) Release from
aphidicolin block. Cells were depleted for RPA2, treated with aphidicolin as described in ‘Materials and Methods’ section. After either 0 or 8h after
release from aphidicolin cells were collected and examined by ﬂow cytometry as described in Figure 2b. Black histograms represent RPA2-depleted
cells, and red histograms represent exogenous RPA-expresssing cells. Construct expressed is designated above each set of histograms. Sc2, yeast
RPA2. (b) Schematic of constructs. RPA2 is divided into three domains: phosphorylation domain (PD), DBD and the C-terminus containing the
WHD. XhoI, AﬂII, SpeI and KpnI sites ﬂank the domains (designated above the RPA2 schematic). RPA2 domains are blue and RPA4 domains are
orange. Names of construct represent which PD, DBD, and WHD they contain and are designated to the right of each schematic. DBD-D, RPA2
DBD; DBD-G, RPA4 DBD; Native, natural forms; Hybrid, RPA2 and RPA4 combinations; Core, DBDs only. (c) Native and hybrid expression.
GFP antibody was used to detect exogenous expression. Construct expressed is denoted above each lane; NV, no plasmid vector; position of
GFP-RPA4 (RPA4), GFP-RPA2 (RPA2) are indicated by arrows; NS, non-speciﬁc band that migrates close to position of RPA4-note NV lane.
The non-speciﬁc band overlaps with RPA4 and makes this band appear more intense. (d) Expression and rescue by hybrid constructs. Procedure and
designations are as in Figure 3a. The percentage of cells in S-phase for each construct is shown in each histogram as the mean±standard deviation.
(e) Quantitation of cells in G2/M-phase from experiment shown in (d). Mock- or RPA2 siRNA-treatment is designated below graph. Construct is
designated below each bar of graph. Error bars represent standard deviation.
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for replication in human cells and if RPA4 DBD-G is
suﬃcient for G2/M arrest using ‘core’ constructs
(Figure 5b). Following RPA2 depletion, cells expressing
DBD-D progressed through S-phase, although the eﬃ-
ciency of progression was reduced compared to exogenous
RPA2 (Supplemental Figure S3). In contrast, cells
expressing DBD-G showed a dramatic reduction in pro-
gression through S-phase, similar to RPA4 (Supplemental
Figure S3). These studies do not rule out DBD-G support-
ing a low level of DNA synthesis but demonstrate that
DBD-G activity is similar to RPA4 while DBD-D is
closer to RPA2. The DBD is the domain most highly
conserved between RPA2 and RPA4 (Figure 1), yet one,
DBD-D, is functional for replication and the other,
DBD-G, is defective for replication and causes unstressed
cells to arrest in G2/M.
Function of the L34 loop region of RPA4
There is a short region, noted previously (12), where
RPA2 contains an acidic stretch of amino acids not
found in RPA4 (Figure 6a). The corresponding stretch
of amino acids (aa 108–123) in RPA4 contains a number
of basic residues (Figure 6a). In our studies of ‘core’ DBD
constructs (Figure 5a and d), we observed  5kDa size
diﬀerence in the mobility of RPA2 DBD-D and RPA4
DBD-G polypeptides, consistent with substantial diﬀer-
ences in charge in this region (Figure 6b). This region
lies in the 3–4 loop (L34) of the known DBD-D structure
and is postulated to be ﬂexible, as it only appears in one of
nine known structures of RPA2 (18). Protein modeling
revealed that although predicted structures of DBD-G
are similar to DBD-D, the predicted electrostatic surface
potentials of the L34 region of these two domains are very
diﬀerent (Figure 6b).
Using site-directed mutagenesis, we generated a form of
GFP-RPA2 where the acidic L34 loop was replaced with
the basic L34 loop from RPA4 (called 2Basic) and a form
of GFP-RPA4 where the basic L34 was replaced with the
acidic L34 loop from RPA2 (called 4Acidic). Exogenous
expression of 2Basic in RPA2-depleted HeLa cells resulted
in G2/M arrest, similar to, but more pronounced than,
exogenous expression of RPA4 (Figure 6c, see also
Figure 5e). Conversely, 4Acidic expression resulted in per-
centages of G2/M cells more similar to RPA2-expressing
cells (Figure 6c). This suggests that L34 is critical for
RPA2 function, and that the RPA4 basic loop is both
necessary and suﬃcient for the arrest phenotype
observed for constructs containing DBD-G. S-phase pro-
gression was also examined using synchronized cells.
Neither 2Basic nor 4Acidic could support S-phase pro-
gression (Figure 6d) indicating that L34 from RPA4 is
suﬃcient to inactivate RPA2, but that the corresponding
loop from RPA2 does not restore function to RPA4.
Since RPA4 is deﬁcient for DNA replication and proﬁ-
cient for G2/M arrest, we tested whether or not exogenous
RPA4 expression could inhibit endogenous RPA2
function. Cells were transfected with GFP-RPA2 or
GFP-RPA4 without depletion of endogenous RPA2.
One would predict a dominant negative phenotype to
result in an increase in S-phase cells (replication deﬁ-
ciency), a G2/M checkpoint (arrest proﬁciency), or both.
We were unable to detect an appreciable increase in
S- or G2/M-phase after exogenous RPA4 expression
(Figure 6e). However, expression of 2Basic, which
contains the L34 region (only 16 aa) of RPA4, caused a
detectable increase in G2/M arrested cells (Figure 6e).
This is consistent with 2Basic having a stronger phenotype
in RPA2-depleted cells than RPA4. The absence of a
dominant negative phenotype with RPA4 could be the
result of expression levels, protein stability, or complex
preference. Recently, RPA complexes containing 2Basic
or RPA4 (but not 4Acidic) have been shown to inhibit
wild-type RPA function in SV40 replication in vitro (13).
Together these ﬁndings suggest that 2Basic, and probably
RPA4, can inhibit normal RPA2 functions in cells when
expressed at high enough levels, and that the basic L34
region of RPA4 is suﬃcient for this inhibition.
DISCUSSION
RPA4 and RPA2 have diﬀerent cellular functions
All cells require DNA repair to maintain the integrity of
their genome, and canonical RPA is required for multiple
DNA repair pathways. We have shown that RPA4 may be
able to participate in DNA repair processes: (i) RPA4 is
able to localize to sites of DNA damage, (ii) expression of
RPA4 supports checkpoint activation after DNA damage
and (iii) reduces high g-H2AX levels that occur after
depletion of RPA2. These studies also show that, unlike
RPA2, RPA4 does not support chromosomal DNA rep-
lication. We believe that incomplete replication causes the
appearance of g-H2AX foci and leads to cell-cycle arrest
in unstressed, proliferating cells expressing only RPA4.
We also have recently shown that RPA4 can support
some repair processes in vitro (Mason, unpublished
data). Thus, both forms appear to support DNA repair,
but only RPA2 supports DNA replication and cell-cycle
progression.
The contribution of the individual regions of RPA2 and
RPA4 to cellular replication
Hybrid subunits were used to identify the region of RPA4
is responsible for its phenotypes. From these studies, we
were able to demonstrate: (i) the putative phosphorylation
domain of RPA4 has no eﬀect on DNA replication, (ii) the
C-terminus of RPA4 can support a substantial amount of
cellular DNA replication and (iii) the DBD G, the
putative DBD of RPA4, is necessary and suﬃcient to
prevent cellular DNA replication.
The C-terminus of RPA2 has been shown to be essential
for SV40 DNA replication in vitro (32). This ﬁnding was
conﬁrmed by a recent study by Mason et al. who showed
that an RPA complex containing the RPA4 C-terminus
substituted for the normal RPA2 C-terminus (hybrid 224)
is defective in SV40 DNA replication in vitro (13).
However, we show that in human cells, a substantial
amount of chromosomal DNA replication was observed
in cells containing only hybrid 224. This indicates that the
Nucleic AcidsResearch, 2010, Vol.38,No. 3 855inability of the hybrid 224 to support in vitro DNA repli-
cation is speciﬁc to the SV40 system and not to cellular
replication. These conclusions are also consistent with the
observation in yeast that the C-terminus of RPA2 is dis-
pensable for cell viability (30).
The putative DBD of RPA4 is responsible for the
observed phenotypes (replication defect and G2/M
arrest). This domain shares the highest sequence identity
between RPA2 and RPA4, especially in regions that have
been shown to be important for the global fold (18).
Figure 6. Examination of basic/acidic constructs. (a) Alignment of loop3-4 (L34) regions of RPA2 and RPA4. The L34 region lies in the DBD of
each protein. Amino acid position is designated to the left and right of the sequence. Identical residues are denoted by asterisk, and the positively and
negatively charged residues that diﬀer between RPA2 and RPA4 are denoted with   or +. (b) Protein modeling and predicted electrostatic surface
potential for RPA2 and RPA4 DBDs. The known structure of DBD-D (18) is shown to the left, and one model of DBD-G (Geno3D) is shown to
the right. Important features are denoted as follows: L12, loop between b-sheets 1 and 2; L34, loop between b-sheets 3 and 4; L45, loop between
b-sheets 4 and 5; cleft, putative DNA-binding cleft. For electrostatic surface potential: red, acidic; blue, basic. Western blot of expression is shown in
the middle and constructs are denoted above each lane and identiﬁed to the left and right of the blot (G-RPA or G-DBD indicates GFP-tagged
protein). NS, non-speciﬁc bands. (c) Cell-cycle phenotypes for exogenous basic/acidic constructs. Cells were transfected and examined at 96h.
post-transfection as in Figure 3a. The percentage of cell in G2/M phase is shown in each histogram as the mean±standard deviation.
(d) Aphidicolin block and release of cells containing 2Basic and 4Acidic. Data generated in same experiment shown in Figure 5a: cells were
treated and designated as described in Figure 5a. (e) Dominant negative analysis. In the presence of endogenous RPA2, exogenous RPA2, RPA4
and 2Basic were expressed. Overlays of the DNA histograms are shown. Black histograms represent cells with no vector and red histograms represent
cells expressing indicted RPA form.
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RPA complex, has weak ssDNA-binding activity, and
participates in speciﬁc protein–protein interactions (4).
Recent biochemical characterization of an alternative
RPA complex (containing RPA4) demonstrated that it
has properties indistinguishable from the canonical RPA
(13). This suggests that the phenotypes caused by RPA4
are most likely due to changes in protein–protein interac-
tions. In particular, the loop (L34) region shows a large
charge diﬀerence between RPA4 and RPA2. By
manipulating this region in RPA2 and RPA4, we were
able to show that RPA2 containing the L34 loop region
of RPA4 behaved similarly to RPA4. Given that this loop
is ﬂexible, we propose that this loop region may be respon-
sible for altering speciﬁc protein–protein interactions in
the cell that result in the inability to replicate DNA and
trigger cell-cycle arrest. We are currently investigating this
possibility.
RPA4 and cell-cycle regulation
Initial observations found that RPA4 protein was detected
predominantly in quiescent cells, and RPA2 was detected
predominantly in proliferating cells (12). For example,
RPA4 was originally found to be expressed in colon
mucosal cells, which are mostly non-proliferative (12).
More recently it has been noted that RPA2 expression is
increased and correlates with the severity of colon cancer
(8). Keshav et al. (12) suggested that preferential expres-
sion of RPA4 versus RPA2 may be indicative of tissue
diﬀerentiation and cell quiescence. We have shown that
RPA4 is unable to support DNA replication, and that
DBD-G (speciﬁcally, L34 of RPA4) also causes accumu-
lation of cells in G2/M. Our data are consistent with
Keshav’s hypothesis. RPA4 cannot support DNA replica-
tion but does appear to participate in DNA recognition
and DNA repair. This suggests a model in which cells
expressing predominantly RPA4 would be able to
maintain their genome but not carry out DNA replication
or cell proliferation. This model also suggests either
that expression of RPA4 contributes to modulation of
cell proliferation or that RPA4 expression must be
down-regulated for proliferation to occur.
A prediction of this model is that if both RPA4 and
RPA2 are present in cells, the RPA4 should compete
with endogenous levels of RPA2 and inhibit DNA repli-
cation and cell-cycle progression. This type of inhibition
was observed in vitro: a RPA complex containing RPA4
inhibits the function of canonical RPA2 containing
complex in SV40 DNA replication (13). We did not
observe a G2/M arrest in cells expressing both RPA2
and RPA4; however, we did observe a dominant
negative phenotype when both RPA2 and RPA2Basic
were expressed (Figure 6e). One explanation for these
results is that exogenous RPA4 expression in this system
may simply not be high enough to observe an eﬀect in the
presence of endogenous RPA2, but that a similar level of
expression of the 2Basic subunit competes more eﬃciently
with wild-type RPA2 and results in a phenotype. We are
currently examining whether increasing the expression of
RPA4 using other promoters or diﬀerent cells results in
modulation of cell growth.
The diﬀerent distributions of cells observed in
asynchronous RPA2-depleted cells also suggest an inhib-
itory function for RPA4 in the cell. In asynchronous cells,
we observed an asymmetric distribution of cells in S-phase
when RPA2 is depleted (e.g. Figure 6c). This distribution
is most easily explained by the fact that RPA2 depletion is
gradual, and some percentage of cells will exit G1 and
enter into S-phase before RPA2 is depleted below a
critical level. This asymmetric distribution is not
observed in cells expressing exogenous RPA4 (e.g.
Figure 6c). In these cells, RPA4 is being expressed at
high levels as RPA2 depletion is occurring. If RPA4 did
not inhibit RPA2 function, an asymmetric distribution
similar to the depleted cells should have been observed.
Since it was not, this suggests that the level of RPA4
present was suﬃcient to inhibit cells with residual
(lower) amounts of RPA2 from exiting G1 phase and
entering S-phase. This supports the conclusion that
RPA4 can inhibit RPA2 function.
Together, these analyses support a maintenance
function for RPA4 in non-proliferating cells. These
studies suggest that RPA4 expression levels could have
dramatic eﬀects during development and could help
modulate cell proliferation status.
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